The largest changes from baseline in average weekly pain scores during the 4-week trial were consistently observed in the TTX 30 μg QD and TTX 30 μg BID cohorts, although these changes did not reach statistical significance. 2.2.2.
← all excerpts
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial.
1
—
—